- Current prognostic models for systemic immunoglobulin light chain (AL) amyloidosis are outdated due to improved therapies.
- This review analyzed prognostic factors in AL amyloidosis, categorizing them as disease-specific and patient-specific.
- Traditional baseline biomarkers, like free light chain difference and bone marrow plasma cell burden, are losing prognostic significance.
- The authors conclude there is an urgent need for validation studies and prognostic model refinement.
- Clinicians require updated models to identify high-risk patients who may benefit from additional interventions.
Navigating AL Amyloidosis: The Evolving Landscape of Prognosis and Treatment
Systemic immunoglobulin light chain (AL) amyloidosis, a disorder of misfolded protein deposition that causes progressive organ dysfunction, has long been associated with high mortality [1, 2]. The therapeutic outlook has improved substantially, first with proteasome inhibitors and more recently with daratumumab-based regimens that have become a standard of care [3, 4, 5]. Daratumumab, a monoclonal antibody targeting CD38, has produced high rates of hematologic and organ response, particularly when combined with cyclophosphamide, bortezomib, and dexamethasone [6, 4, 7]. Despite these advances, the prognostic models clinicians rely on for risk stratification were developed before the advent of these highly effective therapies [8]. This has created a critical disconnect, as traditional biomarkers may no longer accurately predict outcomes. A comprehensive new review analyzes this gap, charting the current state of prognostic factors and highlighting the urgent need to refine clinical decision-making tools.
Treatment Progress Outpaces Prognostic Tools
The introduction of daratumumab-based regimens has significantly altered the natural history of AL amyloidosis. This is clearly demonstrated in the landmark ANDROMEDA trial, where patients receiving these modern treatments achieved a 76% 5-year overall survival. This success, however, has exposed a major deficiency in clinical practice: the prognostic models currently in use were developed using data from patient populations treated with therapies that are now considered suboptimal. Because these older models were not designed to account for the deep and rapid clonal responses achieved with contemporary agents, they no longer accurately reflect patient outcomes. This creates a significant risk of mischaracterizing a patient's prognosis, potentially leading to clinical decisions that are not aligned with the true potential for long-term survival in the modern treatment era.
Re-evaluating Traditional Biomarkers
In response to the shifting therapeutic landscape, a new comprehensive review has systematically analyzed prognostic factors in AL amyloidosis to determine their continued relevance. The authors categorized these markers into two primary groups: disease-specific factors, which are further divided into clone-related (reflecting the underlying plasma cell dyscrasia) and organ-related (measuring amyloid-driven organ damage), and patient-specific factors like age and performance status. A central finding is that the prognostic power of several cornerstone baseline biomarkers is fading. Specifically, the difference between involved and uninvolved free light chains (dFLC), long used to quantify the burden of the pathogenic protein, is losing its predictive significance. Similarly, bone marrow plasma cell burden is also becoming less reliable for forecasting outcomes. This decline is a direct consequence of highly effective clone-directed therapies, which can suppress the pathogenic plasma cell clone so profoundly that these initial baseline measurements no longer correlate strongly with long-term survival.
Emerging Markers for Risk Stratification
With traditional baseline markers becoming less informative, the review identifies several emerging approaches better suited for risk stratification in the current era. Many of these are dynamic markers that reflect treatment response over time. One key example is the assessment of minimal residual disease by free light chain mass spectrometry. This highly sensitive technique can detect minute quantities of pathogenic light chains in the blood, providing a much deeper measure of clonal response than conventional assays and allowing for earlier detection of residual or recurring disease. In addition to clonal markers, advanced organ-specific assessments are gaining importance. For instance, cardiac imaging parameters such as global longitudinal strain (GLS) offer a more sensitive view of cardiac involvement. Derived from echocardiography, GLS measures the deformation of the heart muscle, allowing it to detect subtle changes in myocardial function long before they are apparent in the ejection fraction, which is critical for monitoring the organ most often linked to mortality in AL amyloidosis. The review also notes the value of functional measures, such as exercise capacity and quality-of-life scores, which provide a holistic assessment of a patient's condition and response to therapy.
The Urgent Need for Validation and Refinement
The success of modern treatments, exemplified by the 76% 5-year overall survival with daratumumab-based regimens in the ANDROMEDA trial, has created an imperative to update clinical tools. The review concludes there is an urgent need for validation studies to confirm the prognostic utility of both waning traditional markers and emerging dynamic markers within patient cohorts receiving contemporary therapy. Rigorous validation of tools like free light chain mass spectrometry and global longitudinal strain is the first step toward their integration into routine clinical practice. Following validation, the authors stress the urgent need for prognostic model refinement. New models must be developed that incorporate these dynamic, sensitive biomarkers to more accurately identify patients at high risk of progression despite standard anti-plasma cell therapy. Such refined models would enable clinicians to pinpoint individuals who may benefit from intensified or alternative strategies, ensuring that risk stratification keeps pace with therapeutic progress and that treatment decisions are optimized for every patient with AL amyloidosis.
References
1. Wechalekar A, Silowsky J, Daniel E, et al. Cardiac Amyloid Reaching for Extended Survival (CARES): Study Design of Two Placebo-Controlled, Double-Blind, Randomized, International Phase 3 Trials Assessing Cael-101 in Patients with Mayo Stage Iiia or Stage IIIb AL Amyloidosis. Blood. 2021. doi:10.1182/blood-2021-152488
2. Roussel M, Kastritis E, Schönland S, et al. TeclistAMY (EMN40): A Phase 2 trial of teclistamab in patients with previously treated light-chain (AL) amyloidosis. Blood. 2025. doi:10.1182/blood-2025-3974
3. Javed S, Syed T, Fatima H, et al. Efficacy and Safety Profile of Proteasome Inhibitor Based Drug Regimens for Treatment of Newly Diagnosed AL Amyloidosis: A Systematic Review. 2020. doi:10.1182/blood-2020-143106
4. Sun C, Wang X, Zhang R, Xu L, Wang B, Li J. Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis.. Cancer cell international. 2022. doi:10.1186/s12935-022-02635-6
5. Aimo A, Vergaro G, Castiglione V, et al. [Light chain amyloidosis: multidisciplinary management and innovative therapeutic strategies. SIC/ANMCO Consensus document of the Italian Cardiac Amyloidosis Network (RIAC)].. Giornale italiano di cardiologia (2006). 2026. doi:10.1714/4636.46471
6. Gao Y, Yang K, Wang X, Faisal MS, Gong Z. Daratumumab-based regimens in newly diagnosed mayo 2004 stage 3b AL amyloidosis: A systematic review. Blood. 2025. doi:10.1182/blood-2025-7499
7. Mammadzadeh A, Nagaraj M, Sra M, et al. Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA). Blood. 2024. doi:10.1182/blood-2024-208457
8. Chakraborty R, Brailovsky Y, Hanna M, et al. Prognostic factors and progression biomarkers in AL amyloidosis: mapping current knowledge and critical gaps.. Blood. 2026. doi:10.1182/blood.2025031651